Revenue $3.58B, up 4.6% on a year earlier. Revenue per treatment $415, up 1.1%. International dialysis patient service revenues $398.00M, up 13.1%. Diluted EPS $3.40 against $2.04.
| Q3 FY26 | Q2 FY26 | Q3 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $3.58B | $3.55B | $3.42B | +4.6% |
| Operating income | $499.25M | $579.00M | $505.77M | -1.3% |
| Net income | $222.93M | $265.40M | $150.33M | +48.3% |
| Diluted EPS | $3.40 | $4.02 | $2.04 | |
| Operating cash flow | $518.83M | $490.07M | $841.53M | -38.3% |
| Capital expenditures | -$159.49M | -$169.82M | -$166.09M | |
| Free cash flow | $359.34M | $320.25M | $675.44M | -46.8% |
| Q3 FY26 | Q3 FY25 | Year over year | |
|---|---|---|---|
| Revenue per treatment | $415 | $411 | +1.1% |
| International dialysis patient service revenues | $398.00M | $352.00M | +13.1% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Davita (DVA) Q3 FY26 earnings: results and KPIs”, stockatlas.com/companies/DVA/earnings/2026-q3/, data as of 3 November 2026. Links to this page are welcome.
